Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

IV Infusion to Oral Dosing: Conversion Methods

IV Infusion to Oral Dosing: Conversion Methods

The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

One-Compartment Open Model for IV Bolus Administration: General Considerations

One-Compartment Open Model for IV Bolus Administration: General Considerations

The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The co-occurrence of obesity with cancer-related fatigue and their impact on physical function among breast cancer survivors.

Cancer survivorship research & care·2026

Same author

Acute blood pressure reduction exceeding safety and autoregulatory limits following rapid-acting antihypertensives for hypertensive urgency.

Journal of hypertension·2026

Same author

The Time Course of Repolarization Effects of Intravenous Dofetilide: A Pure Class III Antiarrhythmic Agent.

The American journal of cardiology·2025

Same author

Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial.

Cancer chemotherapy and pharmacology·2025

Same author

Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics.

Journal of clinical pharmacology·2024

Same author

The Efficacy of Nitric Oxide-Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patients of African American and Hispanic Origin.

The American journal of medicine·2023

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

Developing a safe intravenous sotalol dosing regimen.

John C Somberg¹, Richard A Preston, Vasant Ranade

¹Division of Clinical Pharmacology, Rush University, Chicago, IL, USA. jsomberg@rush.edu

American Journal of Therapeutics

|June 22, 2010

Summary

This summary is machine-generated.

A new intravenous sotalol formulation requires a 5-hour infusion to match oral dosing safety and efficacy. This study determined optimal dosing for intravenous sotalol, ensuring comparable blood levels to oral administration.

More Related Videos

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

Related Experiment Videos

Last Updated: Jun 12, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Standardized Model of Ventricular Fibrillation and Advanced Cardiac Life Support in Swine

Published on: January 30, 2020

Area of Science:

Pharmacology
Clinical Pharmacy
Drug Development

Background:

An intravenous formulation of sotalol is now available for patients unable to take oral medication.
Establishing a safe and effective intravenous dosing regimen is crucial for patient care.

Purpose of the Study:

To develop a safe dosing regimen for intravenous sotalol.
To ensure intravenous sotalol provides comparable blood levels, efficacy, and safety to oral sotalol.

Main Methods:

A randomized, 2-treatment, 2-period, crossover study was conducted.
Fifteen healthy subjects received 75 mg intravenous sotalol over 2.5 hours and 80 mg oral sotalol.
Pharmacokinetic analysis and simulation studies were used to determine optimal infusion parameters.

Main Results:

Intravenous sotalol over 2.5 hours yielded a significantly higher Cmax than oral administration.
Simulations indicated that extending infusion to 5 hours normalized Cmax to oral levels.
Infusion duration did not impact AUC; pharmacokinetics are linear and dose-proportional.

Conclusions:

A 75 mg intravenous sotalol dose administered over 5 hours is recommended to replace 80 mg oral sotalol.
A 150 mg intravenous sotalol dose over 5 hours is equivalent to 160 mg oral sotalol.
The FDA-approved regimen aligns with these findings for safe and effective substitution.